Posted by Michael Wonder on 22 Nov 2021
Pfizer to provide U.S. Government with 10 million treatments courses of investigational oral antiviral candidate to help combat COVID-19
18 November 2021 - If approved or authorised, Paxlovid (PF-07321332; ritonavir) would be the first oral anti-viral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2.
Pfizer today announced an agreement with the U.S. Government to supply 10 million treatment courses of its investigational COVID-19 oral anti-viral candidate, Paxlovid (PF-07321332; ritonavir), subject to regulatory authorisation from the U.S. FDA.
